Clinical trial

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

NCT04025879

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2019-11-05

PhasePHASE3

Study timeline

Study start (actual)2019-11-05Date precision: day

Registry last updated2026-08-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Carcinoma, Non-Small-Cell Lungunresolved

Interventions

NivolumabBIOLOGICAL

CarboplatinDRUG · verified · RxNorm: carboplatin

CisplatinDRUG · verified · RxNorm: cisplatin

PaclitaxelDRUG · verified · RxNorm: paclitaxel

PemetrexedDRUG · verified · RxNorm: pemetrexed

DocetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

Bristol-Myers Squibblead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China3 Saint PetersburgRussia3 São PauloSão Paulo, Brazil3 ChangshaHunan, China3 ChicagoIllinois, United States2 ParisFrance2 PragueCzechia2 Kaohsiung CityTaiwan2 FuzhouFujian, China2 HoustonTexas, United States1 BostonMassachusetts, United States1 AtlantaGeorgia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04025879 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.